Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 11/20 | 0.67 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2330904 | 0.86 | FPR2 (0.71) | FPR2HCRTR2HCRTR1KDM4E | |
| SCHEMBL2327138 | 0.86 | FPR2 (0.66) | FPR2HCRTR2HCRTR1KDM4E | |
| SCHEMBL2324067 | 0.85 | FPR2 (0.66) | FPR2HCRTR2HCRTR1KDM4E | |
| SCHEMBL2328982 | 0.84 | FPR2 (0.65) | FPR2HCRTR2HCRTR1KDM4E | |
| SCHEMBL1167239 | 0.83 | HCRTR2 (0.75) | HCRTR2HCRTR1 | |
| SCHEMBL2323231 | 0.83 | FPR2 (0.68) | FPR2HCRTR2HCRTR1KDM4EGSK3B | |
| SCHEMBL2327726 | 0.82 | FPR2 (0.75) | FPR2HCRTR2HCRTR1KDM4E | |
| SCHEMBL2331377 | 0.82 | FPR2 (0.72) | FPR2HCRTR2HCRTR1KDM4E | |
| SCHEMBL2324144 | 0.81 | FPR2 (0.69) | FPR2HCRTR2HCRTR1KDM4EGSK3B | |
| SCHEMBL2324572 | 0.81 | FPR2 (0.68) | FPR2HCRTR2HCRTR1KDM4EGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225231-B1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | claimed |
| EP-2225231-B1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | disclosed |